Challenges in Implementing Pharmacogenomics in Clinical Practice
Author Information
Author(s): Jesse J. Swen, Tom W. Huizinga, Hans Gelderblom, Elisabeth G. E. de Vries, Willem J. J. Assendelft, Julia Kirchheiner, Henk-Jan Guchelaar
Primary Institution: Leiden University Medical Center
Hypothesis
What are the challenges to the widespread clinical use of pharmacogenomics?
Conclusion
Pharmacogenomics has the potential to improve drug therapy by personalizing treatment, but its implementation is hindered by a lack of scientific evidence and other challenges.
Supporting Evidence
- Pharmacogenomics aims to personalize drug therapy based on genetic differences.
- FDA-approved pharmacogenomic tests are available but not widely used in practice.
- Challenges include the need for more scientific evidence and guidelines for clinical use.
Takeaway
Pharmacogenomics helps doctors choose the right medicine for each person based on their genes, but it's not used much yet because there are still many problems to solve.
Limitations
The article discusses the limited evidence supporting the clinical benefits of pharmacogenomics and the challenges in its implementation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website